TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03992131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib will be administered per schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib will be administered per schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Rucaparib will be administered per schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucitanib
Description: Lucitanib will be administered per schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Sacituzumab govitecan will be administered per schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Sacituzumab govitecan will be administered per schedule specified in the arm description.
Study: NCT04210167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based training and telephone monitoring
Description: web-based training and telephone monitoring and short message
Study: NCT04224857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT-101
Description: Single or daily dosing at doses A, B, C, D, E, F

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Single or daily dosing at doses A, B, C, D, E, F
Study: NCT04641676

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NGS testing
Description: NGS test will be performed

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NGS testing
Description: NGS test will be performed

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NGS testing
Description: NGS test will be performed
Study: NCT00261976

Intervention type: DRUG
Intervention: Infliximab (Remicade)
Description: This is an non-interventional study. Participants took the study product as part of their medical routine.
Study: NCT03697317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Televideo Lifestyle Coaching
Description: Six month total intervention: Three months of weekly 1-hour televideo healthy lifestyle coaching sessions involving 30 minutes of structured physical activity and 30 minutes of nutrition education and daily healthy lifestyle habit tracking. This is followed by 3 months of healthy lifestyle habit tracking only.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Six months of healthy lifestyle habit tracking with access to written diet and physical activity materials.
Study: NCT00700700

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Cardiac Resynchronization Therapy (CRT)
Description: Initiation of active biventricular pacing/cardiac resynchronization therapy~Devices by Medtronic:~1. Insync Sentry 7298 \& 7299~2. Concerto C174 ASK (Most frequently implanted)~3. Insync III 8042 (PM)~Devices by Guidant/Boston Scientific:~1. Contak Renewal 4 H190 \& H199~2. Contak Renewal 3 H127~Devices by ELA/Sorin:~1. Ovatio CRT 6750

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Cardiac Resynchronization Therapy (CRT)
Description: Initiation of active biventricular pacing/cardiac resynchronization therapy~Devices by Medtronic:~1. Insync Sentry 7298 \& 7299~2. Concerto C174 ASK (Most frequently implanted)~3. Insync III 8042 (PM)~Devices by Guidant/Boston Scientific:~1. Contak Renewal 4 H190 \& H199~2. Contak Renewal 3 H127~Devices by ELA/Sorin:~1. Ovatio CRT 6750
Study: NCT05330676

Intervention type: PROCEDURE
Intervention: coronary artery bypass grafting, valve repair/replacement
Description: cardiovascular surgery with cardiopulmonary bypass

Intervention type: PROCEDURE
Intervention: coronary artery bypass grafting, valve repair/replacement
Description: cardiovascular surgery with cardiopulmonary bypass
Study: NCT00920322

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS 5 x weekly
Description: Patients will receive rTMS five times weekly for 4 weeks
Study: NCT06132971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Beginnings Program
Study: NCT00920322

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS 3 times weekly
Description: Patients will receive rTMS 3 times weekly for 4 weeks
Study: NCT02984722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT03340831

Intervention type: DEVICE
Intervention: Continuous Glucose Monitoring (CGM)
Description: Use of CGM to compare incidence of diabetes events compared to use of a blood glucose meter (BGM)
Study: NCT01361594

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular insulin (intensive treatment)
Description: Titration of the IV insulin rate for glucose goal 100-140 mg/dL

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Insulin (conventional treatment)
Description: Titration of the IV insulin rate for glucose goal 141-180 mg/dl
Study: NCT02716259

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Description: Two sessions of scaling and root planing under local anesthesia and clorhexidine rinse twice/day, 15 days

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Supragingival prophylaxis
Description: Two sessions of scaling and root planing under local anesthesia and sodium fluoride rinse, twice/day, 15 days
Study: NCT02753153

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control surgical protocol
Description: A connective tissue graft will be harvested to the palate or posterior maxilla tuberosity. The dimension of the graft will be previously calculated according to the socket dimensions. The harvesting site will be made with a single edge incision and sutured with 4.0 silk (uninterrupted suture). The connective tissue graft will be reshaped if necessary to be 1-2mm thick and inserted into buccal pouch and sutured with 2 vertical interrupted sutures to be stabilized on the buccal aspect.~The connective tissue graft is then positioned to caver the socket and inserted and sutured in the palatal pouch also by the means of vertical interrupted sutures (polypropylen 6.0).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Test surgical protocol
Description: The filling biomaterial (Bio-Oss®, Geistlich), previously humidified with a saline solution containing doxycycline (1mg/ml) and inserted into the socket without heavy compaction.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket preservation
Description: An atraumatic extraction will be performed in order to preserve the socket bone wall as well as the cervical soft tissues.~Split- thickness pockets will be performed 5-6 mm deep buccally and 3-4 mm deep palatally preserving interproximal papillae. The filling biomaterial (Bio-Oss®, Geistlich), previously humidified with a saline solution containing doxycycline (1mg/ml) and inserted into the socket without heavy compaction. At this level of the surgery, the randomization envelope will be open and either the control or the test surgical protocol will be applied.
Study: NCT06132971

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: New Beginnings Program
Study: NCT03843996

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment - Stratamed
Description: To determine if Stratamed is more effective than standard of care therapy in limiting severity and duration of signs and symptoms of acute inflammation post follicular harvesting procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment - Stratamed
Description: To determine if Stratamed is more effective than standard of care therapy in limiting severity and duration of signs and symptoms of acute inflammation post follicular harvesting procedure.
Study: NCT04020536

Intervention type: DRUG
Intervention: Antibiotics
Description: Local doctors prescribe available antibiotics to the patients according to the guideline and patients' condition

Intervention type: DRUG
Intervention: Antibiotics
Description: Local doctors prescribe available antibiotics to the patients according to the guideline and patients' condition

Intervention type: DRUG
Intervention: Antibiotics
Description: Local doctors prescribe available antibiotics to the patients according to the guideline and patients' condition
Study: NCT02966704

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: intrinsically labeled milk protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: intrinsically labeled milk protein
Study: NCT04249479

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CM Temperature (20° C)
Description: CM will be administered at 20° C (room temperature).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CM Temperature (37° C)
Description: CM will be administered at 37° C (pre-heated).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight
Description: The patients' weight is measured prior to scanning by a technician on a weighing scale available in the scanner room.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight
Description: The patients' weight is measured prior to scanning by a technician on a weighing scale available in the scanner room.
Study: NCT02147171

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VisionAce

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00723229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acyclovir
Description: Acyclovir 400 mg PO BID for 28 days
Study: NCT01062191

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel AG, typical carboxymethylcellulose dressing
Description: 4 X 4, Aquacel silver sheet

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing
Description: Wound dressing
Study: NCT02753153

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket preservation
Description: An atraumatic extraction will be performed in order to preserve the socket bone wall as well as the cervical soft tissues.~Split- thickness pockets will be performed 5-6 mm deep buccally and 3-4 mm deep palatally preserving interproximal papillae. The filling biomaterial (Bio-Oss®, Geistlich), previously humidified with a saline solution containing doxycycline (1mg/ml) and inserted into the socket without heavy compaction. At this level of the surgery, the randomization envelope will be open and either the control or the test surgical protocol will be applied.
Study: NCT00680446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulin G (Ig NextGen 16%)
Description: Weekly or Bi-weekly subcutaneous administration of Immunoglobulin G
Study: NCT02392052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinvention Protocol Participants
Description: A cognitive behavioral therapy (CBT), to enhance self-efficacy skills for caregivers of family members with SCI, with a focus on changing thinking styles to help people make emotional and behavioral changes.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait List
Description: This group will include individuals randomized to receive no treatment for the 18 weeks during which the interventional group will receive the active treatment and have their progress tracked.
Study: NCT01143181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brincidofovir
Description: Brincidofovir (BCV) was administered orally either once or twice weekly for up to 3 months. Treatment may have been extended for an additional 3 months depending a satisfactory review of safety parameters. Subjects could not receive more than a total of 6 months of treatment with BCV without prior approval.
Study: NCT00359983

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenHibrix (Hib-MenCY-TT)
Description: First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenHibrix (Hib-MenCY-TT)
Description: First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib conjugate vaccine (ActHIB)
Description: First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hib conjugate vaccine (ActHIB)
Description: First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose
Study: NCT02320981

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard of Care esophagogastroduodenoscopy (EGD) with measurement of mucosal impedance
Study: NCT02830126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anesthesiology Control Tower Feedback
Description: Clinicians in the Anesthesiology Control Tower will provide extra support for the anesthesiology team in the operating room.
Study: NCT01763515

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laterally wedged insoles
Description: Patients will use laterally wedged insoles with 5o tilt toward medial side and made of ethylene vinyl acetate coated with leather. The medial thickness is 4 mm with lateral thickness of 10 mm.
Study: NCT04573348

Intervention type: DIAGNOSTIC_TEST
Intervention: Savicell's ImmunoBiopsy™
Description: ImmunoBiopsy and ELISA
Study: NCT03262662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: oral varenicline tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: oral varenicline tablets

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief smoking cessation counseling
Description: \~10-minute individual counseling at each of 6 clinic visits

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief smoking cessation counseling
Description: \~10-minute individual counseling at each of 6 clinic visits
Study: NCT01680640

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic
Description: The synbiotic to be used is fructo-oligosacharide with a degree of polymerization \< 10 at 4 g/twice a day (two sticks a day) plus Bifidobacterium animalis subsp. lactis BB-12 as minimum of 10 billion CFU/day (1 capsule a day).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Study: NCT01209234

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-Care Education
Description: Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MRSA Decolonization
Description: Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.
Study: NCT01353651

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment using self expandable nitinol STENTS
Description: A direct stenting will be performed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open repair treatment
Description: The surgeon will perform its usual technique to revascularize the common femoral artery
Study: NCT02324400

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RenaSense Stimulation
Description: RenaSense Catheter, Electrical Stimulation of the Urinary Bladder Wall

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RenaSense Sham Control
Description: RenaSense Catheter,no delivery of stimulation
Study: NCT01140295

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol, senna
Description: Senna dosage: Age 6-12 years: 3 teaspoons or 3 tablets by mouth 2 nights before endoscopy and 1 night before endoscopy. Age \>12 years: 6 teaspoons or 6 tablets by mouth 2 nights before endoscopy and 1 night before endoscopy. A Fleet's rectal enema is administered on the morning of the procedure.~Miralax at a dose of 1.5 grams/kg divided twice a day for two days; maximum of 51 grams per dose. Dissolve each 17 grams (1 capful) PEG-P in 240 mL water or other beverage according to the manufacturer's direction and to give the appropriate amount of PEG solution twice a day for two days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol, senna
Description: Senna dosage: Age 6-12 years: 3 teaspoons or 3 tablets by mouth 2 nights before endoscopy and 1 night before endoscopy. Age \>12 years: 6 teaspoons or 6 tablets by mouth 2 nights before endoscopy and 1 night before endoscopy. A Fleet's rectal enema is administered on the morning of the procedure.~Miralax at a dose of 1.5 grams/kg divided twice a day for two days; maximum of 51 grams per dose. Dissolve each 17 grams (1 capful) PEG-P in 240 mL water or other beverage according to the manufacturer's direction and to give the appropriate amount of PEG solution twice a day for two days.
Study: NCT01966172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: oral ibuprofen 400mg 4 times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Oral Gabapentin 300mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 10 mg morphine orally 4 times daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: oral paracetamol 1000mg four times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: oral paracetamol 1000mg four times daily
Study: NCT02971761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enobosarm
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT02756221

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: One capsule per day for 90 days. Containing 8 x 109 CFU of bacteria /capsule Lactobacillus heleveticus Lafti L10 Bifidobacterium animalis ssp lactis Lafti B94 Enterococcus faecium Rosell-26 Bifidobacterium longum RO175 Bacillus subtills Rosell-179 Inactive ingredients: potato starch, magnesium stearate, ascorbic acid White vegetable capsule size 1

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules identical in shape and color to the probiotics capsules, one capsule per day for 90 days
Study: NCT06424431

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stapler combined with electrocautery
Description: Closure with a closure device combined with electrocoagulation for pancreatic stump closure in distal pancreatectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: simple closure with a closure device
Description: Simple closure with a closure device for pancreatic stump closure in distal pancreatectomy
Study: NCT02390700

Intervention type: BIOLOGICAL
Intervention: Golimumab Intravenous
Description: This is a non-interventional study. Participants with rheumatoid arthritis in Canada will be observed for 24 months.
Study: NCT01600248

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Online ABBT for Chronic Pain in Military
Description: Participants will complete an 8-module, self-paced, online program for chronic pain using Acceptance-Based Behavioural Therapy (ABBT) as the therapeutic modality.
Study: NCT01827995

Intervention type: OTHER
Group type: OTHER
Intervention: Self assessment
Description: Intervention group: Simplified followup Mifepristone at outpatient clinic, followed by the administration of misoprostol 24-48 hours later (in the clinic or at home). The women will not return to the clinic for routine follow up visit, but are given instructions on how to use a checklist and a low sensitivity pregnancy test around day 10-14. They are asked only to return if they have any health problems or screen positively. The low sensitivity urinary-hCG (with HCG of 1000 IU/ml) test will be used. Women will be provided the pregnancy test free of cost along with a pictorial checklist. A research assistant or a nurse will explain in detail how to use the pregnancy test as well as the checklist, and provide phone numbers in case of any questions or doubts. Follow-up interviews will be conducted through home visits or phone (if woman has one) during the next 1-2 days to screen for on-going pregnancies and assess acceptability the self-assessment.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine assessment
Description: Follow up in the clinic
Study: NCT03111459

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Valiant Thoracoabdominal Stent Graft System
Description: The Medtronic Valiant Thoracoabdominal Stent Graft System is made up of two main body components and makes use of several off-the-shelf FDA-approved stent graft components The system is comprised of two investigational devices that include the thoracic bifurcation and the visceral manifold. The thoracic bifurcation is deployed in the thoracic aorta and provides the proximal seal for the device. The two limbs of the thoracic bifurcation allows for continued aortic flow while deploying the visceral segment. The visceral manifold is deployed within the larger 20 mm limb of the thoracic bifurcation to set the stage for the visceral debranching. The branches of the visceral manifold extend to the visceral vessel with the use of covered bridging stents and provide distal seal of the manifold.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Valiant Thoracoabdominal Stent Graft System
Description: The Medtronic Valiant Thoracoabdominal Stent Graft System is made up of two main body components and makes use of several off-the-shelf FDA-approved stent graft components The system is comprised of two investigational devices that include the thoracic bifurcation and the visceral manifold. The thoracic bifurcation is deployed in the thoracic aorta and provides the proximal seal for the device. The two limbs of the thoracic bifurcation allows for continued aortic flow while deploying the visceral segment. The visceral manifold is deployed within the larger 20 mm limb of the thoracic bifurcation to set the stage for the visceral debranching. The branches of the visceral manifold extend to the visceral vessel with the use of covered bridging stents and provide distal seal of the manifold.
Study: NCT02925598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-gel LMA insertion
Description: 'I-gel LMA insertion' was done following anesthesia induction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AuraGain LMA insertion
Description: 'AuraGain LMA insertion' was done following anesthesia induction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ETT insertion
Description: 'ETT insertion' was done following anesthesia induction.